Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
NEW YORK, April 24, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, today announced closing $8.5 million in corporate financing. Anterios is currently conducting Phase 2b clinical trials studying ANT-1207, a patented topical botulinum toxin type A treatment. Clinical indications that are being pursued for ANT-1207 include the treatment of lateral canthal lines (Crow's Feet wrinkles), hyperhidrosis (excessive sweating), and acne. Anterios has previously completed multi-center, double-blind, randomized, controlled, dose-escalation studies for each indication and demonstrated that ANT-1207 was well tolerated and demonstrated clinically and statistically significant efficacy versus controls. Anterios' investors include Ascent Biomedical Ventures, DRW Trading Group, Praesideo Private Equity Partners, Quantum Technology Partners, Scientific Health Development, and The Spring Bay Companies.
"ANT-1207 has the potential to be a significant addition to the treatment modalities available to both aesthetic and medical dermatology," states Timothy C. Flynn, MD, clinical investigator and dermatologist in private practice, the current President of the American Society of Dermatologic Surgery, and Clinical Professor of Dermatology at the University of North Carolina at Chapel Hill. "This is truly a transformative product, with the potential to impact how we treat our patients in three major areas of concern: wrinkles, excessive sweating, and acne."
Clinical trials of ANT-1207 that have been previously completed included approximately 250 subjects. Anterios' Crow's Feet wrinkle study demonstrated that ANT-1207 achieved an improvement in wrinkles both when the patient was smiling and when the patient's face was at rest. Both the Crow's Feet wrinkle study and the hyperhidrosis study demonstrated not only that a single dose of ANT-1207 shows therapeutic benefit for these indications, but also that the duration of such benefit is comparable to that observed with approved injectable botulinum treatments. In a first for a botulinum toxin treatment and in contrast to the current injectable botulinum treatments on the market, Anterios is pursuing an acne indication and holds a world-wide exclusive license for patents covering the treatment of acne with botulinum in either topical or injectable form. Anterios' previously completed acne study demonstrated a clear therapeutic signal that ANT-1207 has the potential to improve acne lesions. The study results were promising and additional development work will further elucidate the benefits of this new potentially highly innovative treatment.
"We are pleased with the clinical results to date and the potential that ANT-1207 holds for the large existing markets representing the indications that we pursuing. This financing ensures that we have the opportunity to continue to prove the safety and efficacy of our topical delivery of botulinum and, eventually, bring it into the practices of physicians worldwide," stated Jon Edelson, MD, CEO and Founder of Anterios.
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.
ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. Botulinum Type A.
About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com
SOURCE Anterios, Inc.